The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis
10.3760/cma.j.issn.0578-1426.2013.07.008
- VernacularTitle:他克莫司治疗重症肌无力疗效及安全性评价
- Author:
Yuping CHEN
;
Wei WANG
;
Zhongkui WANG
;
Dongning WEI
;
Juan ZHANG
- Publication Type:Journal Article
- Keywords:
Myasthenia gravis;
Immunosuppressive drug;
Tacrolimus
- From:
Chinese Journal of Internal Medicine
2013;(7):567-569
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of tacrolimus in patients with generalized myasthenia gravis (MG).Methods A total of 69 cases admitted to our hospital were given 2-6 mg/day tacrolimus (FK506) for 12 months.The MG absolute and relative clinical scores were used to monitor the efficacy of tacrolimus.Clinical evaluation was conducted at month 1,3,6,and 12,while the serum concentration of FK506 was measured at one month after administration of tacromus for one month.Results The therapeutic response presenting as improved muscular strength showed within one month after administration of tacrolimus.The overall response rates (MG relative clinical score≥25％) at month 1,3,6 were 81.2％,87.6％,92.2％ respectively.It reached 93.8％ by the final visit at month 12.MG score to evaluate disease severity decreased significantly as the subjects continued to take tacrolimus.Statistic analysis suggested that the serum concentration of FK506 was correlated with its therapeutic effect.Serum trough levels in remission and response groups [(7.1 ± 3.9) μg/L and (6.3 ± 3.8) pg/L,respectively] were significantly higher than that of no response group [(3.4 ± 1.3) μg/L].The most common adverse effects included hyperglycemia (5 cases),myelosuppression (3 cases),and dizziness tinnitus (3 cases),majority of which were temporary and manageable.Conclusions Our study has shown that tacrolimus significantly improved muscular strength of generalized MG patients.The treatment is well tolerated.The therapeutic effect of tacrolimus is observed within 1 month after initial use.Adverse events were manageable and not common.
